“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
The world is grappling with an unprecedented crisis. The focus remains not only on controlling the spread of Covid-19, but on ensuring the safety of those who are working at the frontlines of the pandemic to contain it and those whose livelihoods have been severely impacted by it.
At Lupin, we are moving ahead with a clear strategy of safety and preparedness. At the onset of the crisis, we set up a centralized ‘Covid-19 Taskforce’ to monitor the situation daily and put in place adequate safeguards to ensure the health and safety of our employees, develop a business continuity plan, and support the communities we operate in.
All our factories have been maximizing the production of life-saving drugs to ensure that despite the ongoing crisis, our drugs remain available for our communities around the world. We have ramped up production of hydroxychloroquine sulphate and Azithromycin – two drugs being explored as potential treatment for Covid-19.
While our manufacturing site employees are committed towards meeting your healthcare needs, we are committed to their health and safety. We have ensured: complete sanitization of our premises, as well as that of the company buses and cabs that our employees use; thermal screening for employees working at sites; providing sanitizers and masks to employees and support staff at all our premises. Additionally, we are also following all protocols and guidelines issued by global health organizations for COVID-19 to keep our employees safe.
Our Supply Chain team is taking all appropriate actions to ensure that any disruption is minimal and we continue to function regularly during this uncertain time.
Our team at Lupin Human Welfare and Research Foundation is dedicating efforts towards production of face masks for personnel involved in essential services; packed meals are also being served in Madhya Pradesh and Rajasthan to migrant workers who have been worst hit in this crisis.
The fact remains that this is a complex situation where despite our best efforts, we all face an uncertain tomorrow. You have our promise that we remain committed to providing you with access to quality healthcare at an affordable price.
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.